Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...
(IN BRIEF) A Phase III trial of Tezspire (tezepelumab) by AstraZeneca and Amgen has shown significant benefits for patients ...
AstraZeneca Plc (NASDAQ:AZN) and Amgen Inc (NASDAQ:AMGN) released topline data from the Phase 3 WAYPOINT trial of Tezspire ...
Amgen (AMGN) and AstraZeneca (AZN) announced top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with ...
The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...
Amgen (AMGN) and AstraZeneca's (AZN) asthma therapy Tezspire hits main goals in the Phase 3 trial for chronic rhinosinusitis ...
TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
THOUSAND OAKS, Calif., Nov. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line ...
Topline results from a phase 3 trial show that tezepelumab statistically significantly reduced the size of nasal polyps and nasal congestion in adults with chronic rhinosinusitis with nasal polyps ...
The following is a summary of “Real-world effectiveness of dupilumab in a European cohort of CRSwNP (CHRINOSOR),” published in the October 2024 issue of Allergy and Immunology by Seys et al. Pivotal ...
Tessa Romero, an analyst from J.P. Morgan, has initiated a new Buy rating on Upstream Bio, Inc. (UPB). Tessa Romero’s rating is based on ...
A study published in Frontiers in Medicine reveals that chronic rhinosinusitis with and without nasal polyps is closely correlated with asthma.A study was done to investigate the ...
Dupilumab significantly improves the day-to-day symptom burden in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback